EUVIMEDOntdek EUVIMED
Crossref

Clinical features and outcomes of 17 children with systemic juvenile xanthogranuloma (sJXG) including five complicated with hemophagocytic lymphohistiocytosis (HLH)

Yunze Zhao iD, Tong Zou iD, Ang Wei iD, Honghao Ma, Hongyun Lian, Dong Wang, Zhigang Li, Tianyou Wang, Rui Zhang iD

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-05955-x ↗

At a glance

Journal article in Annals of Hematology, 2024. Written by Yunze Zhao and 8 co-authors. Institution: Hematology Centre, National Key Clinical Discipline of Pediatric Hematology, National Key Discipline of Pediatrics (Capital Medical University), Beij…. Major MEDLINE topics: Lymphohistiocytosis, Hemophagocytic, Xanthogranuloma, Juvenile. Cited 3 times so far (Crossref); 25 references. Funded by: Beijing Municipal Administration of Hospitals' Youth Program, Beijing research Ward Project, Research and Transformation Application of Clinical Characteristic Diagnosis and Treatment Techniques in the Capital.

SamenvattingSubjectsBibliografische gegevensCiteRelated studies

Abstract (original language)

Juvenile xanthogranuloma (JXG) is primarily limited to the skin, and systemic JXG (sJXG) is rarely reported. Reports of sJXG patients with hemophagocytic lymphohistiocytosis (HLH) are particularly rare. Herein, we conducted a retrospective study of children diagnosed with sJXG in the Hematology Centre of Beijing Children's Hospital from Jan. 2016 to Dec. 2021. The clinical features, laboratory parameters, treatments and outcomes of 17 sJXG patients were investigated, including five complicated with HLH. All sJXG-HLH patients had intermittent fever, rash, hepatosplenomegaly, cytopenia and high levels of soluble CD25, but interferon-γ was almost normal. Patients with sJXG-HLH had a younger diagnosis age (P = 0.035) and were more likely to have skin, liver, and spleen involvement than those without HLH (P = 0.029, P = 0.003, P = 0.003, respectively). Corticosteroids and/or ruxolitinib could be used to control the hyperinflammatory status when HLH was diagnosed. The treatment of sJXG varied, including Langerhans cell histiocytosis (LCH)-based chemotherapy and targeted therapy. The overall response rate of sJXG for first-line and second-line chemotherapy was 50.0% (5/10) and 50% (4/8), respectively. Patients with BRAF V600E mutation showed a response to dabrafenib. There was no significant difference in the overall survival and progression-free survival between sJXG patients without and with HLH (P = 0.12 and P = 0.46, respectively). Therefore, LCH-based chemotherapy could serve as an effective treatment for sJXG patients, and dabrafenib, to some extent, showed efficacy in controlling sJXG in patients with BRAF V600E mutation. The prognosis of sJXG-HLH patients seemed to be comparable to patients without HLH.

Subjects

MeSH terms (MEDLINE)

Lymphohistiocytosis, HemophagocyticXanthogranuloma, JuvenileHumansMaleFemaleChild, PreschoolRetrospective StudiesInfantChildNitrilesTreatment OutcomeProto-Oncogene Proteins B-rafPyrazolesAdolescentAdrenal Cortex HormonesPyrimidines

Author keywords

Hemophagocytic lymphohistiocytosisHepatosplenomegalyPrognosisSystemic juvenile xanthogranuloma

Substances

NitrilesProto-Oncogene Proteins B-rafruxolitinibBRAF protein, humanPyrazolesAdrenal Cortex HormonesPyrimidines

Authors and institutions

  • Hematology Centre, National Key Clinical Discipline of Pediatric Hematology, National Key Discipline of Pediatrics (Capital Medical University), Beijing, 100045, China.
  • Key Laboratory of Major Diseases in Children, Ministry of Education, Nanlishi Road No. 56, Xicheng District, Beijing, 100045, China.
  • Beijing Children's Hospital, Capital Medical University, National Centre for Children's Health in Boarding, Beijing, 100045, China.
  • Hematology Centre, National Key Clinical Discipline of Pediatric Hematology, National Key Discipline of Pediatrics (Capital Medical University), Beijing, 100045, China. ericlzg70@hotmail.com.
  • Key Laboratory of Major Diseases in Children, Ministry of Education, Nanlishi Road No. 56, Xicheng District, Beijing, 100045, China. ericlzg70@hotmail.com.
  • Beijing Children's Hospital, Capital Medical University, National Centre for Children's Health in Boarding, Beijing, 100045, China. ericlzg70@hotmail.com.

ORCID profiles: Yunze Zhao, Tong Zou, Ang Wei, Rui Zhang

Funding

  • Beijing Municipal Administration of Hospitals' Youth Program
  • Beijing research Ward Project
  • Research and Transformation Application of Clinical Characteristic Diagnosis and Treatment Techniques in the Capital
  • National Natural Science Foundation of China
  • Beijing Municipal Administration of Hospitals’ Youth Program

Cite

APA

Zhao, Y., Zou, T., Wei, A., Ma, H., Lian, H., Wang, D., Li, Z., Wang, T., & Zhang, R. (2024). Clinical features and outcomes of 17 children with systemic juvenile xanthogranuloma (sJXG) including five complicated with hemophagocytic lymphohistiocytosis (HLH). Annals of Hematology. https://doi.org/10.1007/s00277-024-05955-x

Vancouver

Zhao Y, Zou T, Wei A, Ma H, Lian H, Wang D, et al. Clinical features and outcomes of 17 children with systemic juvenile xanthogranuloma (sJXG) including five complicated with hemophagocytic lymphohistiocytosis (HLH). Annals of Hematology. 2024. doi:10.1007/s00277-024-05955-x

BibTeX
@article{Zhao2024,
  author = {Zhao, Yunze and Zou, Tong and Wei, Ang and Ma, Honghao and Lian, Hongyun and Wang, Dong and Li, Zhigang and Wang, Tianyou and Zhang, Rui},
  title = {Clinical features and outcomes of 17 children with systemic juvenile xanthogranuloma (sJXG) including five complicated with hemophagocytic lymphohistiocytosis (HLH)},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-05955-x}
}
Start for free →